US Investments Intended To Take Indian Pharma Up The Value Chain: Interview
Chennai: Indian pharmaceutical companies have committed $19.1 billion investments in the US during the SelectUSA Investment Summit 2026, at a time when India's PLI scheme has hardly lowered dependence on China for Active Pharmaceutical Ingredients (APIs). Ravi Uday Bhaskar, former Director General of Pharmexcil, finds that the PLI scheme is being monopolised by "big firms" and the criteria have to…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
